Publicaciones en colaboración con investigadores/as de Hospital Virgen de La Luz de Cuenca (32)

2024

  1. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  2. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  3. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  3. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

2022

  1. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  2. Prediction of chemotoxicity, unplanned hospitalizations and early death in older patients with colorectal cancer treated with chemotherapy

    Cancers, Vol. 14, Núm. 1

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  2. Prediction of unplanned hospitalizations in older patients treated with chemotherapy

    Cancers, Vol. 13, Núm. 6, pp. 1-11

  3. Undertreatment and overtreatment in older patients treated with chemotherapy

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 381-387

2020

  1. Clinical characteristics and outcomes of venous thromboembolic events after hallux valgus surgery: insights from the RIETE registry

    Journal of Thrombosis and Thrombolysis, Vol. 49, Núm. 4, pp. 651-658

  2. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416

  3. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

    Thrombosis Update, Vol. 1

  4. Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study

    Oncologist, Vol. 25, Núm. 10, pp. e1516-e1524

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  2. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2018

  1. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

  2. Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days

    American Heart Journal, Vol. 206, pp. 1-10